Proven Efficacy Beyond BRCA1
Explore the efficacy ZEJULA can offer patients with ovarian cancer in the following indications1:
Maintenance Treatment of Patients With Recurrent Ovarian Cancer Who Are in Complete or Partial Response to Platinum-Based Chemotherapy
Treatment of Patients With Advanced Ovarian Cancer After Three or More Chemotherapies Whose Cancer Is Associated With HRD+ Status
FDA-approved indications for ZEJULA1
BRCA, breast cancer susceptibility gene; BRCA+, BRCA mutated; BRCA−, not BRCA mutated; HRD, homologous recombination deficiency; HRD+, homologous recombination deficiency positive; HRD−, homologous recombination deficiency negative.
Reference: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: GSK, Inc; October 2019.